Press release
New Paper Highlights Clinical Utility of Natera’s Renasight™ Test in the Management of Kidney Disease
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new paper in
About this update from Natera, Inc.
[{"type":"text","content":" AUSTIN, Texas--(BUSINESS WIRE)--\nNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new paper in Pediatric Nephrology, which highlights the clinical utility of Renasight™ in aiding the diagnosis and management of kidney disease. The publication can be found here.\n\nThis paper reviews the case of a 16-year-old patient with sickle cell disease (SCD) and kidney cysts. Natera’s Renasight test, a genetic testing panel that analyzes 385 genes related to kidney disease, was administered to examine whether an additional genetic cause may have been contributing to the patient’s kidney cysts. The test identified genetic variants which led to a diagnosis of autosomal dominant polycystic kidney disease (ADPKD), in addition to the patient’s SCD.\n\nSCD and ADPKD are distinct genetic conditions that affect kidney function. SCD is routinely diagnosed in newborns whereas ADPKD is most often diagnosed in adulthood. While both conditions may include the presence of kidney cysts, the two conditions have different treatment regimens and complications. Furthermore, there is the potential that treatments effective in one condition may be harmful to the other.\n\n“In identifying the presence of these two conditions, genetic testing has provided crucial information impacting how we will monitor and treat this patient,” said Asifhusen Mansuri, MD, Pediatric Nephrologist with Augusta University Medical Center. “We would not typically be looking for ADPKD in patients like this, and had it not been for this test, the patient’s ADPKD might have gone undiagnosed. Genetic testing is providing care teams with key insights that will better inform disease management and potentially slow disease progression for patients with kidney disease.”\n\nChronic kidney disease affects more than 10% of the global population. The New England Journal of Medicine published a study1 in 2019 showing that 89% of patients with positive findings on a multi-gene genetic test had actionable clinical implications.\n\n“This paper brings awareness to the complex nature of managing patients with dual monogenic conditions and the benefit to using broad-panel genetic testing,” said Sangeeta Bhorade, MD, Chief Medical Officer of Organ Health at Natera. “To our knowledge, this manuscript is the first report of an individual with bot...